NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $227,000 | +1.3% | 13,369 | -0.8% | 0.05% | -11.5% |
| Q3 2020 | $224,000 | -49.2% | 13,482 | -29.3% | 0.06% | -52.7% |
| Q2 2020 | $441,000 | +32.4% | 19,057 | +2.3% | 0.13% | +2.4% |
| Q1 2020 | $333,000 | -6.5% | 18,632 | +13.0% | 0.13% | +14.5% |
| Q4 2019 | $356,000 | -9.6% | 16,491 | +48.9% | 0.11% | -32.5% |
| Q2 2019 | $394,000 | -28.1% | 11,075 | -32.1% | 0.16% | -25.2% |
| Q1 2019 | $548,000 | +1.3% | 16,319 | -0.8% | 0.22% | -16.2% |
| Q4 2018 | $541,000 | -25.9% | 16,456 | +37.4% | 0.26% | -20.0% |
| Q3 2018 | $730,000 | +29.9% | 11,979 | +4.1% | 0.32% | +14.0% |
| Q2 2018 | $562,000 | -66.2% | 11,511 | -26.4% | 0.28% | -61.8% |
| Q1 2018 | $1,662,000 | +80.8% | 15,637 | +1.7% | 0.75% | +56.7% |
| Q4 2017 | $919,000 | – | 15,381 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |